当前位置：
X-MOL 学术
›
Br. J. Cancer
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Genomic profiling of multiple breast cancer reveals inter-lesional heterogeneity.
British Journal of Cancer ( IF 6.4 ) Pub Date : 2020-01-13 , DOI: 10.1038/s41416-019-0713-1 Soomin Ahn 1 , Hyun Jeong Kim 1 , Eunyoung Kang 2 , Eun-Kyu Kim 2 , Se Hyun Kim 3 , Jee Hyun Kim 3 , In Ah Kim 4 , So Yeon Park 1
British Journal of Cancer ( IF 6.4 ) Pub Date : 2020-01-13 , DOI: 10.1038/s41416-019-0713-1 Soomin Ahn 1 , Hyun Jeong Kim 1 , Eunyoung Kang 2 , Eun-Kyu Kim 2 , Se Hyun Kim 3 , Jee Hyun Kim 3 , In Ah Kim 4 , So Yeon Park 1
Affiliation
|
BACKGROUND
Multiplicity in breast cancer is common. Studies on multiple breast cancers have revealed high concordance in biomarker status among individual lesions. However, genomic differences among multiple lesions are not well-established. We aimed to investigate the potential genomic heterogeneity of multiple breast cancer.
METHODS
Twenty-one patients with radiologically and histologically evident multiple breast cancer with similar histology were included. Two lesions from each of the 21 patients were selected, and biomarker status was evaluated for each lesion. Capture-based targeted next-generation sequencing was performed using a cancer gene panel consisting of 170 genes.
RESULTS
We identified discordance in intrinsic subtype in 2 (10%) of the 21 patients. Pathogenic mutations were detected in 13 of the 21 patients, of whom 11 shared oncogenic variants in the two lesions. The remaining two patients yielded different mutation results for TP53, ATM, and PIK3CA. Difference in copy number alteration was observed in 7 (33%) of the 21 patients including ERBB2 (n = 2), FGFR1 (n = 2), and FGFR2 (n = 1) genes.
CONCLUSION
Despite similar histologic features of the individual lesions, inter-lesional genomic difference was identified in more than one-third of the patients. Inter-lesional genomic heterogeneity needs to be considered when performing a genomic test in multiple breast cancers.
更新日期：2020-01-13
京公网安备 11010802027423号